Plus   Neg

Stock Alert: Mesoblast Shares Up 10%

The stock, Mesoblast Ltd. (MESO), has been trading in the range of $3.12 - $20.57 for the past one year, and is currently trading at $13.27, up $1.23 or 10.17%.

The company announced that an expanded access protocol or EAP has been initiated in the United States for compassionate use of its allogeneic mesenchymal stem cell or MSC product candidate remestemcel-L in the treatment of COVID-19 infected children with cardiovascular and other complications of multisystem inflammatory syndrome (MIS-C).

Patients aged between two months and 17 years may receive one or two doses of remestemcel-L within five days of referral under the EAP.

The protocol was filed with the U.S. FDA and provides physicians with access to remestemcel-L for an intermediate-size patient population1 under Mesoblast's existing Investigational New Drug or IND application.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT